Nomura Healthcare Fund Class R (DLRHX)

Fund Assets	745.76M
Expense Ratio	1.46%
Min. Investment	$0.00
Turnover	4.00%
Dividend (ttm)	0.63
Dividend Yield	2.24%
Dividend Growth	n/a
Payout Frequency	Annual
Ex-Dividend Date	Dec 2, 2025

Previous Close	28.46
YTD Return	13.12%
1-Year Return	34.09%
5-Year Return	73.74%
52-Week Low	23.39
52-Week High	28.46
Beta (5Y)	0.81
Holdings	108
Inception Date	Jan 28, 2010

About DLRHX

Macquarie Healthcare Fund Class R is an actively managed mutual fund specializing in the healthcare sector. Its primary function is to provide investors with exposure to a diversified portfolio of companies operating in medical and healthcare industries, including pharmaceuticals, medical device manufacturers, health maintenance organizations (HMOs), hospitals, and nursing homes. The fund aims to capitalize on the significant long-term growth potential within global healthcare markets by investing across multiple segments of the industry, sometimes with a focus on specific sectors such as biotechnology or service providers. Managed by Liu-Er Chen since 2007, the fund leverages deep industry expertise and quantitative analysis to inform its investment decisions. It benchmarks its performance against the Russell 3000 Healthcare Index and is designed for investors seeking targeted healthcare exposure within their broader portfolio allocations. Macquarie Healthcare Fund Class R is notable for its dedicated healthcare focus, relatively low barriers to entry for certain share classes, and a stated net expense ratio of 1.46%. It plays a significant role in offering investors thematic access to the health sector, allowing participation in an industry that often demonstrates resilience and innovation regardless of broader economic cycles.

• Fund Family: Nomura
• Category: Health
• Performance Rating: High
• Risk Rating: Below Average
• Stock Exchange: NASDAQ
• Ticker Symbol: DLRHX
• Share Class: Class R
• Index: Russell 3000 Healthcare TR

Performance

DLRHX had a total return of 34.09% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.06%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
DLHIX	Institutional Class	0.96%
DLHAX	Class A	1.21%
DLHCX	Class C	1.96%

Top 10 Holdings

38.98% of assets

Name	Symbol	Weight
UCB SA	UCB	5.20%
AbbVie Inc.	ABBV	4.20%
Eli Lilly and Company	LLY	4.17%
Regeneron Pharmaceuticals, Inc.	REGN	3.91%
UnitedHealth Group Incorporated	UNH	3.89%
Pfizer Inc.	PFE	3.84%
Merck & Co., Inc.	MRK	3.69%
Gilead Sciences, Inc.	GILD	3.54%
AstraZeneca PLC	AZN	3.27%
Elevance Health, Inc.	ELV	3.25%

Dividend History

Ex-Dividend	Amount	Pay Date
Dec 2, 2025	$2.84116	Dec 2, 2025
Dec 3, 2024	$3.26278	Dec 4, 2024
Dec 4, 2023	$1.39633	Dec 5, 2023
Dec 2, 2022	$2.274	Dec 5, 2022
Dec 3, 2021	$1.476	Dec 6, 2021
Dec 4, 2020	$1.496	Dec 7, 2020

Data Sources: Tiingo, Twelve Data, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Twelve Data. Several fund data points are also provided by Finnhub.

Last checked:

Aug 27, 2026

Data Sources Report a data error